| Sep 30 |
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
|
| Sep 30 |
Dow Dips 300 Points; Emcore Shares Spike Higher
|
| Sep 30 |
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
|
| Sep 30 |
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
|
| Sep 30 |
Bristol, Prime Medicine in deal to develop T-cell therapies
|
| Sep 30 |
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
|
| Sep 30 |
Prime Medicine Unveils Strategically Focused Pipeline
|
| Sep 30 |
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
|
| Sep 30 |
Prime to narrow gene editing research as it strikes deal with Bristol Myers
|
| Sep 4 |
Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns
|
